Last Price$2.95.0%
Market Cap$2,541.3M
LTM Long-Term Investments
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
5/10
11,448.4% undervalued
Heart Test Laboratories, Inc. Long-Term Investments
Annual
Quarterly
LTM
Crunching data... Almost there!
| Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|
| Long-Term Investments | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for HSCS
and see if it's the right time to invest.
Heart Test Laboratories, Inc. (HSCS) Long-Term Investments comparison analysis
General
LTM Long-Term Investments
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Heart Test Laboratories, Inc.HSCS
$0.0
N/A
N/A
N/A
Median Peer Set
$0.0
(100.0%)
(72.4%)
0.0%
Koninklijke Philips N.V.PHG
$920.6M
(16.6%)
(5.6%)
13.1%
Abbott LaboratoriesABT
$886.0M
10.9%
2.8%
0.1%
Boston Scientific CorporationBSX
$555.0M
34.4%
10.4%
3.9%
Edwards Lifesciences CorporationEW
$307.9M
(47.3%)
(44.8%)
(12.1%)
DexCom, Inc.DXCM
$0.0
(100.0%)
(100.0%)
N/A
Medtronic plcMDT
$0.0
(100.0%)
(100.0%)
(100.0%)
Insulet CorporationPODD
$0.0
(100.0%)
(100.0%)
(100.0%)
Zimmer Biomet Holdings, Inc.ZBH
$0.0
(100.0%)
N/A
N/A
STERIS plcSTE
$0.0
(100.0%)
(100.0%)
(100.0%)
Stryker CorporationSYK
$0.0
(100.0%)
(100.0%)
N/A
HSCS key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|
% growth | 0.1 0.0% | 0.0 (60.1%) | 0.0 (43.9%) | 0.0 (64.2%) | 0.0 261.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 27.6% | 0.0 58.3% | 0.0 45.1% | 0.0 45.7% | 0.0 67.3% |
| Operating Expenses | 3.8 | 2.6 | 4.7 | 6.1 | 6.3 |
| Research & Development Expenses (R&D) | 2.0 | 1.7 | 3.0 | 2.5 | 2.9 |
| Selling, General & Administrative Expenses (SG&A) | 1.8 | 0.9 | 1.7 | 3.7 | 3.4 |
% margin | (3.8) (5,949.0%) | (2.6) (10,030.2%) | (4.7) (32,765.6%) | (6.1) (118,698.3%) | (6.3) (33,902.0%) |
| Interest Income | 0.0 | 0.1 | 0.4 | 0.2 | 0.0 |
| Interest Expense | 0.0 | 0.1 | 0.4 | 0.2 | 0.4 |
| Pre-tax Income | (3.8) | (2.5) | (4.8) | (6.4) | (6.6) |
% effective tax rate | 0.0 (0.6%) | 0.1 (5.3%) | (0.3) 5.2% | 484.5 (7,624.8%) | 0.0 0.0% |
% margin | (3.8) (5,973.4%) | (2.6) (10,081.1%) | (4.6) (31,851.8%) | (490.9) (9,531,151.3%) | (6.6) (35,511.9%) |
| EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
| Diluted EPS | (115.69) | (77.89) | (137.94) | (6,173.88) | (18.74) |
% margin | (3.7) (5,834.2%) | (2.3) (8,928.7%) | (4.4) (30,822.2%) | (6.1) (118,139.8%) | (6.2) (33,096.7%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Heart Test Laboratories, Inc.'s Long-Term Investments?
As of today, Heart Test Laboratories, Inc.'s last 12-month Long-Term Investments is $0.0, based on the financial report for Oct 31, 2024 (Q4’2024).
2) What is Heart Test Laboratories, Inc.'s Long-Term Investments growth rate?
Over the last year, Heart Test Laboratories, Inc.'s Long-Term Investments growth was N/A. The average annual Long-Term Investments growth rates for Heart Test Laboratories, Inc. have been N/A over the past three years, N/A over the past five years.